Technical Data

128337-ML650
Clone Type
Polyclonal
Host
Rabbit
Source
Human
Conjugate
MaxLight™650
Isotype
IgG
Grade
Affinity Purified
Applications
WB
Crossreactivity
Hu
Accession #
NM_000597.2, NP_000588.2
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze
Notes
Preservative Free
Rabbit Anti-IGFBP2 (Insulin-like Growth Factor-binding Protein 2, IBP-2, IGF-binding Protein 2, IGFBP-2, BP2, IBP2) (MaxLight 650)

MaxLight™650 is a new Far-IR stable dye conjugate comparable to Alexa Fluor™647, DyLight™649, Cy5™ and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (655nm); Emission (676nm); Extinction Coefficient 250,000.

The insulin like growth factors (IGFs) are the major growth- promoting factors in the plasma. IGFs are secreted by a variety of cells and exert a multitude of effects on cellular survival, growth and differentiation. The A and B domains of IGFs are identical to insulin. IGF initiates their biological action through binding to the type IGF receptor (IGF-1R), a heterotrimeric protein complex with a tyrosine kinase activity. The IGF-IIR lacks the kinase activity and is actually identical to the mannose- 6-phophate receptor. Unlike most other peptide hormones, IGFs are complexed with specific binding proteins in the plasma known IGF Binding proteins (IGFBPs). At least 6 related IGFBPs (IGFBP1-6) have been well characterized. Recently, IGFBP-7/Mac25/prostacyclin- stimulating factor (PSF)/tumor adhesion factor (TAF) was originally identified as a cDNA derived from leptomeninges. These proteins are present in plasma in high concentration as compared to the membrane IGFRs. Therefore, IGFBPs have the potential to modulate the IGF action. IGFBPs have been shown to either inhibit or stimulate the IGF effects. The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable mid region, and the conserved C-terminal domain. Human IGFBPs share approximately 36% identity. Recently several groups of cysteine-rich proteins with discrete, but striking, structural and functional similarities to the IGFBPs. This has led to the proposal of an IGFBP superfamily, comprised of the IGFBPs and these IGFBP-related proteins (IGFBP-rP1-9).
Applications
Suitable for use in Western Blot. Other applications not tested.
Recommended Dilution
Optimal dilutions to be determined by the researcher.
Amino Acid Sequence
MLPRVGCPALPLPPPPLLPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ
Storage and Stability
Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
Immunogen
Full length human IGFBP2, aa1-328 (NP_000588.2).
Form
Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.
Purity
Purified by Protein A affinity chromatography.
Specificity
Recognizes human IGFBP2.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
No references available
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net